Revenue distribution by sectors:

• Ophthalmology: approx. 85%
• Optical products and services: approx. 10%
• Other healthcare services: approx. 5%

TOP 3 Markets:

1. China: approx. 70%
2. Southeast Asia: approx. 15%
3. North America: approx. 10%

Huaxia Eye Hospital Group Co., Ltd. generates the majority of its revenue from ophthalmology, which is the company's core competency. The Chinese market is the largest, attributed to the high population density and increasing demand for medical services.

Southeast Asia and North America are also significant markets, with the company benefiting from the growing internationalization and expansion in these regions. Diversification into optical products and other healthcare services also contributes to the revenue structure.

Production Sites: Mainly in China

Huaxia Eye Hospital Group Co., Ltd. is a leading company in the field of ophthalmology in China. The group operates a variety of eye clinics and medical facilities throughout the country. The production of medical devices and products used in their clinics is mainly carried out in China. This allows the company to optimize costs and streamline logistics.

As the company is heavily focused on the domestic market, the production facilities are strategically located near the main clinics and urban centers to ensure quick supply and high availability.

Revenue Growth: Estimated 18% (2026) Market Expansion: Focus on Southeast Asia and the Middle East

Huaxia Eye Hospital Group Co., Ltd. is pursuing a growth strategy that focuses on geographical expansion and technological innovation. The company plans to expand its presence in Southeast Asia and the Middle East to capitalize on the increasing demand for ophthalmology services in these regions.

In addition, the company is investing in advanced technologies and digital health solutions to enhance the efficiency and quality of its services. This includes the implementation of AI-based diagnostic tools and the expansion of their telemedicine offerings.

Through strategic partnerships and acquisitions, Huaxia Eye Hospital Group aims to strengthen its market position and tap into new patient groups. These measures are intended to enable the company to sustain revenue growth and increase competitiveness.

Imported Materials: Medical devices and equipment, pharmaceutical products

Main supplying countries: USA, Germany, Japan

Huaxia Eye Hospital Group Co., Ltd. mainly imports medical devices and equipment needed for ophthalmological treatments and surgeries. These materials are crucial for maintaining high standards in ophthalmology.

The USA, Germany, and Japan are leading countries in the production of advanced medical technologies and pharmaceutical products. Therefore, Huaxia Eye Hospital Group sources many of its specialized devices and medications from these countries to ensure that they can provide their patients with the best possible care.

Market Share: Estimated 10-15% in the Chinese ophthalmology market (2026)
Revenue Growth: 18% (2025)
Net Profit Margin: 12% (2025)

Huaxia Eye Hospital Group Co., Ltd. has a significant competitive advantage in the Chinese ophthalmology market. This is due to their specialized expertise and a wide network of clinics that allows them to serve a large number of patients.

The company benefits from the increasing demand for ophthalmology services in China, particularly due to the aging population and the growing prevalence of eye diseases. Their revenue growth of 18% in 2025 demonstrates their ability to effectively capitalize on this demand.

Additionally, their net profit margin of 12% contributes to a solid financial foundation that enables them to invest in new technologies and services to further enhance their competitive advantage.

Institutional Investor Share: 45% (estimated, 2026)
Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in Huaxia Eye Hospital Group Co., Ltd. is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company, indicating a stable financial performance and growth prospects.

In 2026, no significant insider transactions were reported. This could suggest that the management and other insiders are satisfied with the current company strategy and valuation. A lack of insider sells can also be seen as a positive signal, indicating confidence in the company's future development.

Market share of Huaxia Eye Hospital Group Co., Ltd.: 12% (2026, estimated)

Top competitors and their market shares:

1. Aier Eye Hospital Group Co., Ltd.: 25%
2. Bright Eye Hospital Group: 18%
3. C-MER Eye Care Holdings Limited: 15%
4. Huaxia Eye Hospital Group Co., Ltd.: 12%
5. He Eye Specialist Hospital: 10%
6. Other Regional Eye Care Providers: 20%

Huaxia Eye Hospital Group Co., Ltd. holds a significant market share of approximately 12% in the Chinese ophthalmology market, making them one of the leading providers. The largest competitor is Aier Eye Hospital Group Co., Ltd., which dominates the market with a 25% share.

The moat of Huaxia Eye Hospital Group mainly consists of their specialized expertise in ophthalmology, a well-established network of clinics, and strong brand recognition in certain regions of China. However, compared to Aier Eye Hospital Group, which has a broader network and a stronger financial base, their moat is less pronounced.

Aier Eye Hospital Group has built a stronger moat through extensive investments in technology and research, as well as their international expansion. This enables them to offer innovative treatments and reach a larger patient base.

Overall, Huaxia Eye Hospital Group has a solid market share and some competitive advantages, but competitors, especially Aier Eye Hospital Group, are better positioned in terms of market presence and innovation capabilities.

Revenue Growth: 18% (2025) Profit Growth: 15% (2025) Market Share in China: 12% (2025)

In 2025, Huaxia Eye Hospital Group Co., Ltd. experienced strong revenue growth of 18%, attributed to increasing demand for eye treatments and expansion into new regions. The 15% profit growth during the same period indicates that the company operates efficiently and can maintain its margins.

The company has expanded its market share in China to 12%, signaling successful implementation of its growth strategy. Continuous investment in technology and the opening of new clinics further strengthen its market position.

Overall, the robust revenue and profit growth, along with the increasing market share, suggest that Huaxia Eye Hospital Group Co., Ltd. is a solid investment, especially for investors interested in the expansion of the healthcare sector.

Dividend Yield: 2.5% (2025)
Dividend Growth: 5% (annually on average over the last 3 years)

Huaxia Eye Hospital Group Co., Ltd. paid out a dividend yield of 2.5% in 2025. The company has followed a consistent dividend policy in recent years, with an average annual dividend growth of 5% over the last three years.

The reliability of dividend payments is supported by the company's stable financial performance and strong market position in the healthcare sector. Analysts expect that the company will be able to continue paying dividends at a similar level in the coming years, provided it remains economically stable and successfully implements its growth strategies.